Advertisement

Advertisement

24th SUO Annual Meeting

bladder cancer

Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy

Bishoy M. Faltas, MD, of Weill Cornell Medicine, discusses the biology of upper tract urothelial carcinoma and how it affects treatment, noting that most of these tumors are luminal papillary with a T...

prostate cancer

Sumanta K. Pal, MD, on Prostate Cancer: Impact of the Microbiome on Immune Therapy

Sumanta K. Pal, MD, of City of Hope, discusses the ways in which the composition of the gut microbiome may impact the outcome of immune therapy. Methods such as fecal microbiome transplant hold promis...

prostate cancer

Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II findings from the Neptune study of neoadjuvant olaparib plus androgen-deprivation therapy followed by radical prostate...

prostate cancer

Stephen J. Freedland, MD, on Managing Prostate Cancer in Transgender Women

Stephen J. Freedland, MD, of Cedars-Sinai Medical Center, discusses the incidence of prostate cancer in transgender women. Although the rates of disease appear lower than in cisgender men, Dr. Freedla...

bladder cancer

Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment

Mark D. Tyson, MD, MPH, of the Mayo Clinic School of Graduate Medical Education, discusses the first results from BOND-003, a phase III study of intravesical cretostimogene grenadenorepvec monotherapy...

prostate cancer

Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate

Samson W. Fine, MD, of Memorial Sloan Kettering Cancer Center, discusses the evolving spectrum of atypical intraductal proliferations in the prostate, from high-grade prostatic intraepithelial neoplas...

prostate cancer
genomics/genetics

William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review

William J. Catalona, MD, of Northwestern University Feinberg School of Medicine, reviews the genetic landscape in prostate cancer, including BRCA2 and ATM, two important mutations for aggressive disea...

Advertisement

Advertisement




Advertisement